CL2014000897A1 - Factor de transcripcion artificial que comprende una proteina de dedo de zinc polidactilica dirigida especificamente a un promotor de gen receptor fusionado a un dominio de proteina inhibidor o activador, una secuencia de localizacion nuclear y un dominio de transduccion; composicion farmaceutica que lo comprende; y su uso. - Google Patents

Factor de transcripcion artificial que comprende una proteina de dedo de zinc polidactilica dirigida especificamente a un promotor de gen receptor fusionado a un dominio de proteina inhibidor o activador, una secuencia de localizacion nuclear y un dominio de transduccion; composicion farmaceutica que lo comprende; y su uso.

Info

Publication number
CL2014000897A1
CL2014000897A1 CL2014000897A CL2014000897A CL2014000897A1 CL 2014000897 A1 CL2014000897 A1 CL 2014000897A1 CL 2014000897 A CL2014000897 A CL 2014000897A CL 2014000897 A CL2014000897 A CL 2014000897A CL 2014000897 A1 CL2014000897 A1 CL 2014000897A1
Authority
CL
Chile
Prior art keywords
domain
inhibitor
pharmaceutical composition
transcription factor
zinc finger
Prior art date
Application number
CL2014000897A
Other languages
English (en)
Spanish (es)
Inventor
Josef Flammer
Albert Neutzner
Alice Huxley
Original Assignee
Aliophtha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliophtha Ag filed Critical Aliophtha Ag
Publication of CL2014000897A1 publication Critical patent/CL2014000897A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2014000897A 2011-10-11 2014-04-10 Factor de transcripcion artificial que comprende una proteina de dedo de zinc polidactilica dirigida especificamente a un promotor de gen receptor fusionado a un dominio de proteina inhibidor o activador, una secuencia de localizacion nuclear y un dominio de transduccion; composicion farmaceutica que lo comprende; y su uso. CL2014000897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11

Publications (1)

Publication Number Publication Date
CL2014000897A1 true CL2014000897A1 (es) 2014-11-21

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000897A CL2014000897A1 (es) 2011-10-11 2014-04-10 Factor de transcripcion artificial que comprende una proteina de dedo de zinc polidactilica dirigida especificamente a un promotor de gen receptor fusionado a un dominio de proteina inhibidor o activador, una secuencia de localizacion nuclear y un dominio de transduccion; composicion farmaceutica que lo comprende; y su uso.

Country Status (21)

Country Link
US (1) US20140296129A1 (https=)
EP (1) EP2766484A2 (https=)
JP (1) JP2014530607A (https=)
KR (1) KR20140079780A (https=)
CN (1) CN103998609A (https=)
AU (1) AU2012323032A1 (https=)
BR (1) BR112014008456A2 (https=)
CA (1) CA2851560A1 (https=)
CL (1) CL2014000897A1 (https=)
CO (1) CO6930308A2 (https=)
EA (1) EA201490531A1 (https=)
HK (1) HK1197083A1 (https=)
IL (1) IL231865A0 (https=)
IN (1) IN2014CN02586A (https=)
MA (1) MA36970A1 (https=)
MX (1) MX2014004331A (https=)
PH (1) PH12014500786A1 (https=)
SG (1) SG11201400701WA (https=)
TN (1) TN2014000117A1 (https=)
WO (1) WO2013053719A2 (https=)
ZA (1) ZA201401960B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524545T1 (de) * 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ527476A (en) * 2001-02-21 2006-06-30 Novartis Ag Zinc finger binding domains for nucleotide sequence ANN
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
EP1929032A4 (en) * 2005-09-30 2009-11-04 Oklahoma Med Res Found REGULATION OF GOOD LIKE RECEPTORS ON STEM CELLS
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
EP2411518A2 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
EP2509594A1 (en) * 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
BR112014008456A2 (pt) 2017-04-11
ZA201401960B (en) 2015-06-24
MX2014004331A (es) 2014-11-26
EA201490531A1 (ru) 2014-08-29
IL231865A0 (en) 2014-05-28
EP2766484A2 (en) 2014-08-20
SG11201400701WA (en) 2014-08-28
AU2012323032A1 (en) 2014-04-03
JP2014530607A (ja) 2014-11-20
KR20140079780A (ko) 2014-06-27
PH12014500786A1 (en) 2021-08-09
HK1197083A1 (en) 2015-01-02
IN2014CN02586A (https=) 2015-08-07
CA2851560A1 (en) 2013-04-18
WO2013053719A3 (en) 2013-06-27
MA36970A1 (fr) 2016-03-31
CO6930308A2 (es) 2014-04-28
CN103998609A (zh) 2014-08-20
US20140296129A1 (en) 2014-10-02
TN2014000117A1 (en) 2015-07-01
WO2013053719A2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
CL2014000897A1 (es) Factor de transcripcion artificial que comprende una proteina de dedo de zinc polidactilica dirigida especificamente a un promotor de gen receptor fusionado a un dominio de proteina inhibidor o activador, una secuencia de localizacion nuclear y un dominio de transduccion; composicion farmaceutica que lo comprende; y su uso.
CL2013003450A1 (es) Composicion que contiene oxintomodulina, un polimero de polietilenglicol y 9-fluorenilmetoxicarbonilo o 2-sulfo-9-fluorenilmetoxicarbonilo; metodos de uso.
BRPI1009413A2 (pt) emulsões e adesivos contendo proteína e produção e uso dos mesmos
EP2783338A4 (en) MOBILE DIGITAL COUPLING AT POINT OF SALE
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
BR112013032369A2 (pt) composição de resina, método para melhorar a adesão da referida composição de resina e uso de pelo menos um promotor de adesão
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
ECSP11011557A (es) Mimético de smac
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
DK3536333T3 (da) Depotsystem der omfatter glatirameracetat
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX356091B (es) Composiciones de escoria que comprenden látex y métodos de uso.
BR112012001316A2 (pt) inibidores de pequena molécula potente de autofagia, e métodos de uso dos mesmos.
CU20110029A7 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
MX390891B (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
DK3656758T3 (da) Mellemprodukter til fremstilling af c-terminale hsp90-inhibitorer
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
BR112013022883A2 (pt) aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese
HRP20181398T1 (hr) Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
CL2013000734A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.